XTX Topco Ltd Has $896,000 Stock Position in Relx Plc (NYSE:RELX)

XTX Topco Ltd lifted its stake in shares of Relx Plc (NYSE:RELX - Free Report) by 135.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 19,716 shares of the technology company's stock after purchasing an additional 11,354 shares during the quarter. XTX Topco Ltd's holdings in Relx were worth $896,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of RELX. JPMorgan Chase & Co. grew its holdings in shares of Relx by 14.6% during the third quarter. JPMorgan Chase & Co. now owns 826,481 shares of the technology company's stock worth $39,225,000 after buying an additional 104,999 shares in the last quarter. LGT Group Foundation purchased a new position in shares of Relx during the 4th quarter worth $257,000. Paradigm Asset Management Co. LLC boosted its holdings in shares of Relx by 17.1% during the fourth quarter. Paradigm Asset Management Co. LLC now owns 81,600 shares of the technology company's stock worth $3,706,000 after purchasing an additional 11,900 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in Relx by 120.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 12,066 shares of the technology company's stock valued at $548,000 after purchasing an additional 6,588 shares during the last quarter. Finally, Merit Financial Group LLC purchased a new position in Relx during the fourth quarter worth about $301,000. 15.02% of the stock is currently owned by institutional investors and hedge funds.

Relx Trading Up 1.4 %

Shares of NYSE:RELX traded up $0.72 during midday trading on Tuesday, reaching $52.79. The company had a trading volume of 271,680 shares, compared to its average volume of 714,981. The company has a debt-to-equity ratio of 1.46, a quick ratio of 0.47 and a current ratio of 0.52. Relx Plc has a 1-year low of $40.25 and a 1-year high of $52.86. The firm has a market cap of $97.70 billion, a price-to-earnings ratio of 28.39, a price-to-earnings-growth ratio of 2.73 and a beta of 0.84. The company has a fifty day simple moving average of $49.39 and a two-hundred day simple moving average of $48.06.

Relx Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Wednesday, June 25th. Stockholders of record on Friday, May 9th will be paid a $0.5586 dividend. The ex-dividend date is Friday, May 9th. This is an increase from Relx's previous semi-annual dividend of $0.23. This represents a dividend yield of 1.6%. Relx's dividend payout ratio is 59.68%.

Analyst Ratings Changes

RELX has been the topic of several recent analyst reports. Redburn Atlantic initiated coverage on shares of Relx in a report on Wednesday, January 8th. They set a "buy" rating on the stock. StockNews.com downgraded Relx from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. Morgan Stanley restated an "overweight" rating on shares of Relx in a research note on Wednesday, April 16th. The Goldman Sachs Group initiated coverage on Relx in a report on Wednesday, March 26th. They set a "buy" rating for the company. Finally, Barclays raised shares of Relx from an "equal weight" rating to an "overweight" rating in a research report on Friday, March 14th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy".

About Relx

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.